Filing Details

Accession Number:
0001140361-24-049871
Form Type:
13G Filing
Publication Date:
2024-12-17 19:00:00
Filed By:
Oaktree Fund Advisors, LLC
Company:
Bioxcel Therapeutics Inc. (NASDAQ:BTAI)
Filing Date:
2024-12-18
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Oaktree Fund Advisors, LLC 0 822,944 1.6%
OAKTREE CAPITAL MANAGEMENT LP 0 1,901,131 3.6%
Oaktree Capital Group Holdings GP, LLC 0 2,724,075 5.2%
Oaktree Capital Holdings, LLC 0 2,724,075 5.2%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of class is calculated based on 49,628,948 shares of Common Stock outstanding on December 17, 2024, based on information received from the Issuer, as increased by the 2,724,075 shares of Common Stock issuable upon exercise of the Warrants reported herein.


SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of class is calculated based on 49,628,948 shares of Common Stock outstanding on December 17, 2024, based on information received from the Issuer, as increased by the 2,724,075 shares of Common Stock issuable upon exercise of the Warrants reported herein.


SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of class is calculated based on 49,628,948 shares of Common Stock outstanding on December 17, 2024, based on information received from the Issuer, as increased by the 2,724,075 shares of Common Stock issuable upon exercise of the Warrants reported herein.


SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of class is calculated based on 49,628,948 shares of Common Stock outstanding on December 17, 2024, based on information received from the Issuer, as increased by the 2,724,075 shares of Common Stock issuable upon exercise of the Warrants reported herein.


SCHEDULE 13G


 
Oaktree Fund Advisors, LLC
 
Signature:/s/ Henry Orren
Name/Title:Henry Orren / Authorized Signatory
Date:12/18/2024
 
OAKTREE CAPITAL MANAGEMENT LP
 
Signature:/s/ Henry Orren
Name/Title:Henry Orren / Authorized Signatory
Date:12/18/2024
 
Oaktree Capital Group Holdings GP, LLC
 
Signature:/s/ Henry Orren
Name/Title:Henry Orren / Authorized Signatory
Date:12/18/2024
 
Oaktree Capital Holdings, LLC
 
Signature:/s/ Henry Orren
Name/Title:Henry Orren / Authorized Signatory
Date:12/18/2024
Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of December 18, 2024 Exhibit 99.2 Schedule of Direct Warrant Holders